Liver Disease Treatments: The Global Market

Table of Contents

CHAPTER 1: INTRODUCTION

• STUDY OBJECTIVES
• REASONS FOR DOING THIS STUDY
• INTENDED AUDIENCE
• SCOPE OF THE STUDY
• METHODOLOGY
• INFORMATION SOURCES
• ABOUT THE AUTHOR
• RELATED REPORTS
• BCC ONLINE SERVICES
• DISCLAIMER

CHAPTER 2: SUMMARY

• SUMMARY
• SUMMARY TABLE GLOBAL SALES OF LIVER DISEASE TREATMENTS, THROUGH 2014 ($ MILLIONS)
• SUMMARY FIGURE GLOBAL SALES OF LIVER DISEASE TREATMENTS, 2007-2014 ($ MILLIONS)

CHAPTER 3: OVERVIEW

• DEFINITIONS
• THE LIVER
  • LIVER FUNCTIONS
    • Metabolism
    • Drug Disposition
    • Bile Formation
    • Other Functions
  • COMMON SYMPTOMS OF LIVER DISEASE
    • Jaundice
    • Cholestasis
    • Liver Enlargement
    • Ascites
    • Portal Hypertension
    • Liver Encephalopathy
    • Liver Failure
    • Other Common Symptoms
  • LIVER DISEASES
• TABLE 1 TYPES OF LIVER DISEASES
  • VIRUS-INDUCED LIVER DISEASE
    • Acute Hepatitis
      • Hepatitis A
      • Hepatitis B
      • Hepatitis C
      • Hepatitis D
    • Chronic Hepatitis
      • Alcohol-induced Chronic Hepatitis
      • Chronic Active Hepatitis
      • Chronic Persistent Hepatitis
• LIVER TUMORS
  • Benign Liver Tumors
    • Hepatocellular Adenoma
    • Hemangioma
  • Malignant Liver Tumors
    • Hepatocellular Carcinoma
    • Metastatic Liver Cancer
• CONGENITAL LIVER DEFECTS
  • Biliary Atresia
  • Choledochal Cyst
• AUTOIMMUNE LIVER DISORDERS
  • Hemochromatosis
  • Wilson' s Disease
  • Autoimmune Hepatitis
• ALCOHOL-INDUCED LIVER DISEASE
  • Fatty Liver
  • Alcoholic Hepatitis
  • Alcoholic Cirrhosis
• CHRONIC LIVER DISEASE
  • Cirrhosis
  • Fibrosis
• NON-ALCOHOLIC FATTY LIVER

CHAPTER 4: REGULATORY ISSUES

• TABLE 2 APPROVED DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
• TABLE 2 (CONTINUED)
• TABLE 3 NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
• FIGURE 1 NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
• TABLE 4 NEW DRUG APPLICATIONS FOR DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
• TABLE 5 RECALLS OF DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
  • Hepatitis B
  • Hepatitis C
  • Hepatitis D
  • Chronic Hepatitis
  • Alcohol-induced Chronic Hepatitis
  • Chronic Active Hepatitis
  • Chronic Persistent Hepatitis
• LIVER TUMORS
  • Benign Liver Tumors
  • Hepatocellular Adenoma
  • Hemangioma
  • Malignant Liver Tumors
  • Hepatocellular Carcinoma
  • Metastatic Liver Cancer
• CONGENITAL LIVER DEFECTS
  • Biliary Atresia
  • Choledochal Cyst
• AUTOIMMUNE LIVER DISORDERS
  • Hemochromatosis
  • Wilson' s Disease
  • Autoimmune Hepatitis
• ALCOHOL-INDUCED LIVER DISEASE
  • Fatty Liver
  • Alcoholic Hepatitis
  • Alcoholic Cirrhosis
• CHRONIC LIVER DISEASE
  • Cirrhosis
  • Fibrosis
• NON-ALCOHOLIC FATTY LIVER

CHAPTER 4: REGULATORY ISSUES

• TABLE 2 APPROVED DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
• TABLE 2 (CONTINUED)
• TABLE 3 NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
• FIGURE 1 NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
• TABLE 4 NEW DRUG APPLICATIONS FOR DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
• TABLE 5 RECALLS OF DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
• TABLE 19 IMMUNOSUPPRESSIVE AGENTS USED TO TREAT AUTOIMMUNE HEPATITIS
• ANTIMETABOLITES
• TABLE 20 ANTI-METABOLITES USED TO TREAT AUTOIMMUNE HEPATITIS
• ALCOHOL-INDUCED LIVER DISEASE
• ANABOLIC STEROIDS
• TABLE 21 ANABOLIC STEROIDS USED TO TREAT ALCOHOLIC LIVER DAMAGE
• ALCOHOL ABUSE DRUGS
• TABLE 22 ALCOHOL ABUSE DRUGS USED TO TREAT ALCOHOLIC LIVER DAMAGE
• CHRONIC LIVER DISEASE
• ANTI-REJECTION MEDICATION
• TABLE 23 ANTI-REJECTION MEDICATIONS
• ANTI-INFECTIVES
• TABLE 24 ANTI-INFECTIVES
• ANTIFUNGAL PROPHYLAXIS
• TABLE 25 ANTIFUNGAL PROPHYLAXIS FOR LIVER TRANSPLANT RECIPIENTS
• NON-ALCOHOLIC FATTY LIVER
• GALLSTONE SOLUBILIZING AGENTS
• TABLE 26 GALLSTONE SOLUBILIZING AGENTS USED TO TREAT NON- ALCOHOLIC FATTY LIVER DISEASE
• OTHER DRUGS
• TABLE 27 OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE

CHAPTER 7: INDUSTRY STRUCTURE

• HEPATITIS
• HEPATITIS VACCINE
• TABLE 28 HEPATITIS VACCINE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 2 HEPATITIS VACCINE: MARKET SHARE BY MANUFACTURER, 2008
• NUCLEOSIDE ANALOGS
• TABLE 29 NUCLEOSIDE ANALOGS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 3 NUCLEOSIDE ANALOGS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• NUCLEOTIDE ANALOGS
• TABLE 19 IMMUNOSUPPRESSIVE AGENTS USED TO TREAT AUTOIMMUNE HEPATITIS
• ANTIMETABOLITES
• TABLE 20 ANTI-METABOLITES USED TO TREAT AUTOIMMUNE HEPATITIS
• ALCOHOL-INDUCED LIVER DISEASE
• ANABOLIC STEROIDS
• TABLE 21 ANABOLIC STEROIDS USED TO TREAT ALCOHOLIC LIVER DAMAGE
• ALCOHOL ABUSE DRUGS
• TABLE 22 ALCOHOL ABUSE DRUGS USED TO TREAT ALCOHOLIC LIVER DAMAGE
• CHRONIC LIVER DISEASE
• ANTI-REJECTION MEDICATION
• TABLE 23 ANTI-REJECTION MEDICATIONS
• ANTI-INFECTIVES
• TABLE 24 ANTI-INFECTIVES
• ANTIFUNGAL PROPHYLAXIS
• TABLE 25 ANTIFUNGAL PROPHYLAXIS FOR LIVER TRANSPLANT RECIPIENTS
• NON-ALCOHOLIC FATTY LIVER
• GALLSTONE SOLUBILIZING AGENTS
• TABLE 26 GALLSTONE SOLUBILIZING AGENTS USED TO TREAT NON- ALCOHOLIC FATTY LIVER DISEASE
• OTHER DRUGS
• TABLE 27 OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE

CHAPTER 7: INDUSTRY STRUCTURE

• HEPATITIS
• HEPATITIS VACCINE
• TABLE 28 HEPATITIS VACCINE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 2 HEPATITIS VACCINE: MARKET SHARE BY MANUFACTURER, 2008
• NUCLEOSIDE ANALOGS
• TABLE 29 NUCLEOSIDE ANALOGS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 3 NUCLEOSIDE ANALOGS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• NUCLEOTIDE ANALOGS
• TABLE 30 NUCLEOTIDE ANALOGS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER: 2008 (%)
• FIGURE 4 NUCLEOTIDE ANALOGS TO TREAT HEPATITS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• INTERFERONS
• TABLE 31 INTERFERONS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 5 INTERFERONS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• IMMUNE GLOBULINS
• TABLE 32 IMMUNE GLOBULINS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 6 IMMUNE GLOBULINS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• LIVER TUMORS
• CHEMOTHERAPY
• TABLE 33 CHEMOTHERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 7 CHEMOTHERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TARGETED THERAPY
• TABLE 34 TARGETED THERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 8 TARGETED THERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• AUTOIMMUNE DISEASES
• CHELATING AGENTS
• TABLE 35 CHELATING AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 9 CHELATING AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• CORTICOSTEROIDS
• TABLE 36 CORTICOSTEROIDS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 10 CORTICOSTEROIDS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• IMMUNOSUPPRESSIVE AGENTS
• TABLE 37 IMMUNOSUPPRESSIVE AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 45 OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 19 OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)

CHAPTER 8: DEMAND AND USE

• LIFE EXPECTANCY
• LACK OF KNOWLEDGE
• LACK OF TREATMENT OPTIONS
• INCREASING NUMBER OF PATIENTS
• RESEARCH AND DEVELOPMENT
• INITIATIVES OF VARIOUS ORGANIZATIONS TO INCREASE AWARENESS
• INITIATIVES OF VARIOUS ORGANIZATIONS ... (CONTINUED)

CHAPTER 9: MARKET ANALYSIS

• TABLE 46 GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, BY DISEASE TYPE, THROUGH 2014 ($ MILLIONS)
• FIGURE 20 GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, BY DISEASE TYPE, 2007-2014 ($ MILLIONS)
• HEPATITIS
• MARKET SIZE
• TABLE 47 GLOBAL SALES OF DRUGS TO TREAT HEPATITIS, THROUGH 2014 ($ MILLIONS)
• FIGURE 21 GLOBAL SALES OF DRUGS TO TREAT HEPATITIS, 2007-2014 ($ MILLIONS)
• MARKET OVERVIEW
• Market Overview (Continued)
• LIVER TUMORS
• MARKET SIZE
• TABLE 48 GLOBAL SALES OF DRUGS TO TREAT LIVER TUMORS, THROUGH 2014 ($ MILLIONS)
• FIGURE 22 GLOBAL SALES OF DRUGS TO TREAT LIVER TUMORS, 2007-2014 ($ MILLIONS)
• MARKET OVERVIEW
• AUTOIMMUNE DISEASES
• MARKET SIZE
• TABLE 49 GLOBAL SALES OF DRUGS TO TREAT AUTOIMMUNE DISEASES, THROUGH 2014 ($ MILLIONS)
• TABLE 45 OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 19 OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)

CHAPTER 8: DEMAND AND USE

• LIFE EXPECTANCY
• LACK OF KNOWLEDGE
• LACK OF TREATMENT OPTIONS
• INCREASING NUMBER OF PATIENTS
• RESEARCH AND DEVELOPMENT
• INITIATIVES OF VARIOUS ORGANIZATIONS TO INCREASE AWARENESS
• INITIATIVES OF VARIOUS ORGANIZATIONS ... (CONTINUED)

CHAPTER 9: MARKET ANALYSIS

• TABLE 46 GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, BY DISEASE TYPE, THROUGH 2014 ($ MILLIONS)
• FIGURE 20 GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, BY DISEASE TYPE, 2007-2014 ($ MILLIONS)
• HEPATITIS
• MARKET SIZE
• TABLE 47 GLOBAL SALES OF DRUGS TO TREAT HEPATITIS, THROUGH 2014 ($ MILLIONS)
• FIGURE 21 GLOBAL SALES OF DRUGS TO TREAT HEPATITIS, 2007-2014 ($ MILLIONS)
• MARKET OVERVIEW
  • Market Overview (Continued)
• LIVER TUMORS
• MARKET SIZE
• TABLE 48 GLOBAL SALES OF DRUGS TO TREAT LIVER TUMORS, THROUGH 2014 ($ MILLIONS)
• FIGURE 22 GLOBAL SALES OF DRUGS TO TREAT LIVER TUMORS, 2007-2014 ($ MILLIONS)
• MARKET OVERVIEW
• AUTOIMMUNE DISEASES
• MARKET SIZE
• TABLE 49 GLOBAL SALES OF DRUGS TO TREAT AUTOIMMUNE DISEASES, THROUGH 2014 ($ MILLIONS)
• FIGURE 23 GLOBAL SALES OF DRUGS TO TREAT AUTOIMMUNE DISEASES, THROUGH 2014 ($ MILLIONS)
• MARKET OVERVIEW
• ALCOHOL-INDUCED LIVER DISEASE
• MARKET SIZE
• TABLE 50 GLOBAL SALES OF DRUGS TO TREAT ALCOHOL-INDUCED LIVER DISEASES, THROUGH 2014 ($ MILLIONS)
• FIGURE 24 GLOBAL SALES OF DRUGS TO TREAT ALCOHOL-INDUCED LIVER DISEASES, 2007-2014 ($ MILLIONS)
• MARKET OVERVIEW
• CHRONIC LIVER DISEASES
• MARKET SIZE
• TABLE 51 GLOBAL SALES OF DRUGS TO TREAT CHRONIC LIVER DISEASES, THROUGH 2014 ($ MILLIONS)
• FIGURE 25 GLOBAL SALES OF DRUGS TO TREAT CHRONIC LIVER DISEASES, 2007-2014 ($ MILLIONS)
• MARKET OVERVIEW
• NON-ALCOHOLIC FATTY LIVER DISEASE
• MARKET SIZE
• TABLE 52 GLOBAL SALES OF DRUGS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES, THROUGH 2014 ($ MILLIONS)
• FIGURE 26 GLOBAL SALES OF DRUGS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES, 2007-2094 ($ MILLIONS)
• MARKET OVERVIEW
  • Market Overview (Continued)

CHAPTER 10: DRUG-INDUCED LIVER DISEASE

• DRUG-INDUCED
• DRUGS THAT CAN CAUSE LIVER DISEASE
• ACETAMINOPHEN (TYLENOL)
• STATINS
• NICOTINIC ACID (NIACIN)
• AMIODARONE (CORDARONE)
• NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
• METHOTREXATE (RHEUMATREX, TREXALL)
• ANTIBIOTICS
• TACRINE (COGNEX)
• DISULFIRAM
• VITAMIN SUPPLEMENTS
• TABLE 53 DRUGS THAT CAN CAUSE LIVER DISEASE
• TABLE 53 (CONTINUED)

CHAPTER 11: NEW DEVELOPMENTS

• CLINICAL TRIALS
• TABLE 54 NUMBER OF CLINICAL TRIALS FOR HEPATITIS/ LIVER-INDUCED LIVER DISEASES
• TABLE 55 NUMBER OF CLINICAL TRIALS FOR LIVER TUMORS
• TABLE 56 NUMBER OF CLINICAL TRIALS FOR CONGENITAL LIVER DEFECTS
• TABLE 57 NUMBER OF CLINICAL TRIALS FOR AUTOIMMUNE LIVER DISORDERS
• TABLE 58 NUMBER OF CLINICAL TRIALS FOR ALCOHOL-INDUCED LIVER DISEASES
• TABLE 59 NUMBER OF CLINICAL TRIALS FOR CHRONIC LIVER DISEASES
• TABLE 60 NUMBER OF CLINICAL TRIALS FOR NON-ALCOHOLIC FATTY LIVER DISEASE
• NEW DEVELOPMENTS
• NEW DEVELOPMENTS (CONTINUED)
• STEM CELL RESEARCH

CHAPTER 12: MARKET BY DRUG TYPE

• MARKET SIZE
• TABLE 61 GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, THROUGH 2014 ($ MILLIONS)
• TABLE 61 (CONTINUED)
• FIGURE 27 GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, 2007-2014 ($ MILLIONS)
• MARKET SHARE
• TABLE 62 SHARE OF DRUGS TO TREAT LIVER DISEASES, 2008
• FIGURE 28 SHARE OF DRUGS TO TREAT LIVER DISEASES, 2008 (%)
• VACCINES
• MARKET SIZE
• TABLE 63 GLOBAL SALES OF HEPATITIS VACCINE,THROUGH 2014 ($ MILLIONS)
• FIGURE 29 GLOBAL SALES OF HEPATITIS VACCINE, 2007-2014 ($ MILLIONS)
• ANTIVIRALS
• MARKET SIZE
• TABLE 64 GLOBAL SALES OF NUCLEOSIDE ANALOGS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 30 GLOBAL SALES OF NUCLEOSIDE ANALOGS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• TABLE 65 GLOBAL SALES OF NUCLEOTIDE ANALOGS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 31 GLOBAL SALES OF NUCLEOTIDE ANALOGS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• INTERFERONS
• MARKET SIZE
• TABLE 66 GLOBAL SALES OF INTERFERONS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 32 GLOBAL SALES OF INTERFERONS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• IMMUNE GLOBULINS
• MARKET SIZE
• TABLE 67 GLOBAL SALES OF IMMUNE GLOBULINS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 33 GLOBAL SALES OF IMMUNE GLOBULINS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• CHEMOTHERAPY
• MARKET SIZE
• TABLE 68 GLOBAL SALES OF CHEMOTHERAPY DRUGS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 34 GLOBAL SALES OF CHEMOTHERAPY DRUGS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• TARGETED THERAPY
• MARKET SIZE
• TABLE 69 GLOBAL SALES OF TARGETED THERAPY TO TREAT LIVER CANCER, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 35 GLOBAL SALES OF TARGETED THERAPY TO TREAT LIVER CANCER, BY REGION, 2007-2014 ($ MILLIONS)
• CHELATING AGENTS
• MARKET SIZE
• TABLE 70 GLOBAL SALES OF CHELATING AGENTS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 36 GLOBAL SALES OF CHELATING AGENTS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• CORTICOSTEROIDS
• MARKET SIZE
• TABLE 71 GLOBAL SALES OF CORTICOSTEROIDS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 37 GLOBAL SALES OF CORTICOSTEROIDS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• IMMUNOSUPPRESSIVE AGENTS
• MARKET SIZE
• TABLE 72 GLOBAL SALES OF IMMUNOSUPPRESSIVE AGENTS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 38 GLOBAL SALES OF IMMUNOSUPPRESSIVE AGENTS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• ANTIMETABOLITES
• MARKET SIZE
• TABLE 73 GLOBAL SALES OF ANTIMETABOLITES TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 39 GLOBAL SALES OF ANTIMETABOLITES TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• ANABOLIC STEROIDS
• MARKET SIZE
• TABLE 74 GLOBAL SALES OF ANABOLIC STEROIDS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 40 GLOBAL SALES OF ANABOLIC STEROIDS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• ALCOHOL ABUSE DRUGS
• MARKET SIZE
• TABLE 75 GLOBAL SALES OF ALCOHOL ABUSE DRUGS, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 41 GLOBAL SALES OF ALCOHOL ABUSE DRUGS, BY REGION, 2007-2014 ($ MILLIONS)
• ANTI-REJECTION MEDICATION
• MARKET SIZE
• TABLE 76 GLOBAL SALES OF ANTI-REJECTION MEDICATION TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 42 GLOBAL SALES OF ANTI-REJECTION MEDICATION TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• INFECTION-FIGHTING DRUGS
• MARKET SIZE
• TABLE 77 GLOBAL SALES OF INFECTION-FIGHTING DRUGS TO TREAT LIVER TRANSPLANT PATIENTS, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 43 GLOBAL SALES OF INFECTION-FIGHTING DRUGS TO TREAT LIVER TRANSPLANT PATIENTS, BY REGION, 2007-2014 ($ MILLIONS)
• ANTIFUNGAL PROPHYLAXIS
• MARKET SIZE
• TABLE 78 GLOBAL SALES OF ANTIFUNGAL PROPHYLAXIS IN LIVER TRANSPLANTS, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 44 GLOBAL SALES OF ANTIFUNGAL PROPHYLAXIS IN LIVER TRANSPLANTS, BY REGION, 2007-2014 ($ MILLIONS)
• GALLSTONE SOLUBILIZING AGENTS
• MARKET SIZE
• TABLE 79 GLOBAL SALES OF GALLSTONE SOLUBILIZING AGENTS, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 45 GLOBAL SALES OF GALLSTONE SOLUBILIZING AGENTS, BY REGION, 2007-2014 ($ MILLIONS)
• OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES
• MARKET SIZE
• TABLE 80 GLOBAL SALES OF OTHER DRUGS USED TO TREAT NON- ALCOHOLIC FATTY LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 46 GLOBAL SALES OF OTHER DRUGS USED IN THE TREATMENT OF NON- ALCOHOLIC FATTY LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• CHAPTER 13: PATENT ANALYSIS
• PATENTS BY YEAR
• TABLE 81 TOTAL NUMBER OF PATENTS EACH YEAR, 2005- 2009
• FIGURE 47 TOTAL NUMBER OF PATENTS EACH YEAR, 2005- 2009
• PATENTS BY TYPE
• TABLE 82 NUMBER OF PATENTS BY TYPE, 2005- 2009
• FIGURE 48 NUMBER OF PATENTS BY TYPE, 2005- 2009
• FIGURE 49 PATENTS, SHARE BY TYPE, 2005- 2009 (%)
• PATENTS BY COUNTRY
• TABLE 83 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005- 2009
• FIGURE 50 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005- 2009
• PATENTS BY COMPANY
• TABLE 84 NUMBER OF PATENTS BY COMPANY, 2005- 2009
• FIGURE 51 TOTAL NUMBER OF PATENTS BY COMPANY, 2005- 2009
• PATENTS BY ASSIGNEE
• TABLE 85 NUMBER OF PATENTS BY ASIGNEE, 2005- 2009
• FIGURE 52 NUMBER OF PATENTS BY ASSIGNEE, 2005- 2009

CHAPTER 14: COMPANY PROFILES

• ABBOTT LABORATORIES
• ACTAVIS US
• ALKERMES, INC.
• ALNYLAM PHARMACEUTICALS
• BARR PHARMACEUTICALS
• BAYER SCHERING PHARMA AG
• BIOTEST PHARMACEUTICALS CORPORATION
• BRISTOL-MYERS SQUIBB
• CANGENE CORPORATION
• DEBIOPHARM GROUP
• ELI LILLY & COMPANY
• GALMED MEDICAL RESEARCH, LTD.
• GILEAD SCIENCES, INC.
• GLAXOSMITHKLINE PLC
• HUMAN GENOME SCIENCES
• IDENIX PHARMACEUTICALS INC.
• KINEMED, INC.
• MALLINCKRODT
• MEDA PHARMACEUTICALS
• MERCK & CO.
• NOVARTIS AG
• PAR PHARMACEUTICAL COMPANIES, INC.
• ROCHE
• ROXANE LABORATORIES, INC.
• SANOFI AVENTIS
• SAVIENT PHARMACEUTICALS, INC.
• SCHERING-PLOUGH
• SCYNEXIS
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• THREE RIVERS PHARMACEUTICALS
• VALEANT PHARMACEUTICALS INTERNATIONAL
• WATSON PHARMACEUTICALS, INC.
• WYETH INC.
• ZYDUS PHARMACEUTICALS INC.
• ZYMOGENETICS
• APPENDIX
• ABBREVIATIONS

• SUMMARY TABLE GLOBAL SALES OF LIVER DISEASE TREATMENTS, THROUGH 2014 ($ MILLIONS)
• TABLE 1 TYPES OF LIVER DISEASES
• TABLE 2 APPROVED DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
• TABLE 3 NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
• TABLE 4 NEW DRUG APPLICATIONS FOR DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
• TABLE 5 RECALLS OF DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
• TABLE 6 HEPATITIS BURDEN IN THE UNITED STATES (2005- 2006)
• TABLE 7 INCIDENCE OF ACUTE HEPATITIS BY SEX AND AGE IN THE UNITED STATES (2006)
• TABLE 8 VACCINES FOR HEPATITIS A PREVENTION
• TABLE 9 VACCINES FOR HEPATITIS B PREVENTION
• TABLE 10 NUCLEOSIDE ANALOGS USED TO TREAT HEPATITIS
• TABLE 11 NUCLEOTIDE ANALOGS USED TO TREAT HEPATITIS
• TABLE 12 PROTEASE INHIBITORS USED TO TREAT HEPATITIS
• TABLE 13 INTERFERONS USED TO TREAT HEPATITIS
• TABLE 14 IMMUNE GLOBULINS USED TO TREAT HEPATITIS
• TABLE 15 CHEMOTHERAPUTIC DRUGS USED TO TREAT LIVER CANCER
• TABLE 16 TARGETED THERAPY USED TO TREAT LIVER CANCER
• TABLE 17 DRUGS USED TO TREAT WILSON' S DISEASE
• TABLE 18 CORTICOSTEROIDS USED TO TREAT AUTOIMMUNE HEPATITIS
• TABLE 19 IMMUNOSUPPRESSIVE AGENTS USED TO TREAT AUTOIMMUNE HEPATITIS
• TABLE 20 ANTI-METABOLITES USED TO TREAT AUTOIMMUNE HEPATITIS
• TABLE 21 ANABOLIC STEROIDS USED TO TREAT ALCOHOLIC LIVER DAMAGE
• TABLE 22 ALCOHOL ABUSE DRUGS USED TO TREAT ALCOHOLIC LIVER DAMAGE
• TABLE 23 ANTI-REJECTION MEDICATIONS
• TABLE 24 ANTI-INFECTIVES
• TABLE 25 ANTIFUNGAL PROPHYLAXIS FOR LIVER TRANSPLANT RECIPIENTS
• TABLE 26 GALLSTONE SOLUBILIZING AGENTS USED TO TREAT NON- ALCOHOLIC FATTY LIVER DISEASE
• TABLE 27 OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE
• TABLE 28 HEPATITIS VACCINE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 29 NUCLEOSIDE ANALOGS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 30 NUCLEOTIDE ANALOGS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER: 2008 (%)
• TABLE 31 INTERFERONS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 32 IMMUNE GLOBULINS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 33 CHEMOTHERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 34 TARGETED THERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 35 CHELATING AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 36 CORTICOSTEROIDS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 37 IMMUNOSUPPRESSIVE AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 38 ANTIMETABOLITES TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 39 ANABOLIC STEROIDS TO TREAT ALCOHOL-INDUCED LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 40 ALCOHOL ABUSE DRUGS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 41 ANTI-REJECTION MEDICATION TO TREAT CHRONIC LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 42 ANTI-INFECTIVES TO TREAT CHRONIC LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 43 ANTIFUNGAL PROPHYLAXIS TO TREAT CHRONIC LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 44 GALLSTONE STABILIZING AGENTS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 45 OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 46 GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, BY DISEASE TYPE, THROUGH 2014 ($ MILLIONS)
• TABLE 47 GLOBAL SALES OF DRUGS TO TREAT HEPATITIS, THROUGH 2014 ($ MILLIONS)
• TABLE 48 GLOBAL SALES OF DRUGS TO TREAT LIVER TUMORS, THROUGH 2014 ($ MILLIONS)
• TABLE 49 GLOBAL SALES OF DRUGS TO TREAT AUTOIMMUNE DISEASES, THROUGH 2014 ($ MILLIONS)
• TABLE 50 GLOBAL SALES OF DRUGS TO TREAT ALCOHOL-INDUCED LIVER DISEASES, THROUGH 2014 ($ MILLIONS)
• TABLE 51 GLOBAL SALES OF DRUGS TO TREAT CHRONIC LIVER DISEASES, THROUGH 2014 ($ MILLIONS)
• TABLE 52 GLOBAL SALES OF DRUGS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES, THROUGH 2014 ($ MILLIONS)
• TABLE 53 DRUGS THAT CAN CAUSE LIVER DISEASE
• TABLE 54 NUMBER OF CLINICAL TRIALS FOR HEPATITIS/ LIVER-INDUCED LIVER DISEASES
• TABLE 55 NUMBER OF CLINICAL TRIALS FOR LIVER TUMORS
• TABLE 56 NUMBER OF CLINICAL TRIALS FOR CONGENITAL LIVER DEFECTS
• TABLE 57 NUMBER OF CLINICAL TRIALS FOR AUTOIMMUNE LIVER DISORDERS
• TABLE 58 NUMBER OF CLINICAL TRIALS FOR ALCOHOL-INDUCED LIVER DISEASES
• TABLE 59 NUMBER OF CLINICAL TRIALS FOR CHRONIC LIVER DISEASES
• TABLE 60 NUMBER OF CLINICAL TRIALS FOR NON-ALCOHOLIC FATTY LIVER DISEASE
• TABLE 61 GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, THROUGH 2014 ($ MILLIONS)
• TABLE 62 SHARE OF DRUGS TO TREAT LIVER DISEASES, 2008
• TABLE 63 GLOBAL SALES OF HEPATITIS VACCINE,THROUGH 2014 ($ MILLIONS)
• TABLE 64 GLOBAL SALES OF NUCLEOSIDE ANALOGS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 65 GLOBAL SALES OF NUCLEOTIDE ANALOGS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 66 GLOBAL SALES OF INTERFERONS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 67 GLOBAL SALES OF IMMUNE GLOBULINS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 68 GLOBAL SALES OF CHEMOTHERAPY DRUGS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 69 GLOBAL SALES OF TARGETED THERAPY TO TREAT LIVER CANCER, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 70 GLOBAL SALES OF CHELATING AGENTS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 71 GLOBAL SALES OF CORTICOSTEROIDS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 72 GLOBAL SALES OF IMMUNOSUPPRESSIVE AGENTS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 73 GLOBAL SALES OF ANTIMETABOLITES TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 74 GLOBAL SALES OF ANABOLIC STEROIDS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 75 GLOBAL SALES OF ALCOHOL ABUSE DRUGS, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 76 GLOBAL SALES OF ANTI-REJECTION MEDICATION TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 77 GLOBAL SALES OF INFECTION-FIGHTING DRUGS TO TREAT LIVER TRANSPLANT PATIENTS, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 78 GLOBAL SALES OF ANTIFUNGAL PROPHYLAXIS IN LIVER TRANSPLANTS, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 79 GLOBAL SALES OF GALLSTONE SOLUBILIZING AGENTS, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 80 GLOBAL SALES OF OTHER DRUGS USED TO TREAT NON- ALCOHOLIC FATTY LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 81 TOTAL NUMBER OF PATENTS EACH YEAR, 2005- 2009
• TABLE 82 NUMBER OF PATENTS BY TYPE, 2005- 2009
• TABLE 83 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005- 2009
• TABLE 84 NUMBER OF PATENTS BY COMPANY, 2005- 2009
• TABLE 85 NUMBER OF PATENTS BY ASIGNEE, 2005- 2009

• SUMMARY FIGURE GLOBAL SALES OF LIVER DISEASE TREATMENTS, 2007-2014 ($ MILLIONS)
• FIGURE 1 NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
• FIGURE 2 HEPATITIS VACCINE: MARKET SHARE BY MANUFACTURER, 2008
• FIGURE 3 NUCLEOSIDE ANALOGS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 4 NUCLEOTIDE ANALOGS TO TREAT HEPATITS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 5 INTERFERONS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 6 IMMUNE GLOBULINS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 7 CHEMOTHERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 8 TARGETED THERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 9 CHELATING AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 10 CORTICOSTEROIDS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 11 IMMUNOSUPPRESSIVE AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 12 ANTIMETABOLITES TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 13 ANABOLIC STEROIDS TO TREAT ALCOHOL-INDUCED LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 14 ALCOHOL ABUSE DRUGS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 15 ANTI-REJECTION MEDICATION TO TREAT CHRONIC LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 16 ANTI-INFECTIVES TO TREAT CHRONIC LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 17 ANTIFUNGAL PROPHYLAXIS TO TREAT CHRONIC LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 18 GALLSTONE STABILIZING AGENTS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 19 OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 20 GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, BY DISEASE TYPE, 2007-2014 ($ MILLIONS)
• FIGURE 21 GLOBAL SALES OF DRUGS TO TREAT HEPATITIS, 2007-2014 ($ MILLIONS)
• FIGURE 22 GLOBAL SALES OF DRUGS TO TREAT LIVER TUMORS, 2007-2014 ($ MILLIONS)
• FIGURE 23 GLOBAL SALES OF DRUGS TO TREAT AUTOIMMUNE DISEASES, THROUGH 2014 ($ MILLIONS)
• FIGURE 24 GLOBAL SALES OF DRUGS TO TREAT ALCOHOL-INDUCED LIVER DISEASES, 2007-2014 ($ MILLIONS)
• FIGURE 25 GLOBAL SALES OF DRUGS TO TREAT CHRONIC LIVER DISEASES, 2007-2014 ($ MILLIONS)
• FIGURE 26 GLOBAL SALES OF DRUGS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES, 2007-2094 ($ MILLIONS)
• FIGURE 27 GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, 2007-2014 ($ MILLIONS)
• FIGURE 28 SHARE OF DRUGS TO TREAT LIVER DISEASES, 2008 (%)
• FIGURE 29 GLOBAL SALES OF HEPATITIS VACCINE, 2007-2014 ($ MILLIONS)
• FIGURE 30 GLOBAL SALES OF NUCLEOSIDE ANALOGS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 31 GLOBAL SALES OF NUCLEOTIDE ANALOGS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 32 GLOBAL SALES OF INTERFERONS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 33 GLOBAL SALES OF IMMUNE GLOBULINS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 34 GLOBAL SALES OF CHEMOTHERAPY DRUGS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 35 GLOBAL SALES OF TARGETED THERAPY TO TREAT LIVER CANCER, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 36 GLOBAL SALES OF CHELATING AGENTS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 37 GLOBAL SALES OF CORTICOSTEROIDS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 38 GLOBAL SALES OF IMMUNOSUPPRESSIVE AGENTS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 39 GLOBAL SALES OF ANTIMETABOLITES TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 40 GLOBAL SALES OF ANABOLIC STEROIDS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 41 GLOBAL SALES OF ALCOHOL ABUSE DRUGS, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 42 GLOBAL SALES OF ANTI-REJECTION MEDICATION TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 43 GLOBAL SALES OF INFECTION-FIGHTING DRUGS TO TREAT LIVER TRANSPLANT PATIENTS, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 44 GLOBAL SALES OF ANTIFUNGAL PROPHYLAXIS IN LIVER TRANSPLANTS, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 45 GLOBAL SALES OF GALLSTONE SOLUBILIZING AGENTS, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 46 GLOBAL SALES OF OTHER DRUGS USED IN THE TREATMENT OF NON- ALCOHOLIC FATTY LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 47 TOTAL NUMBER OF PATENTS EACH YEAR, 2005- 2009
• FIGURE 48 NUMBER OF PATENTS BY TYPE, 2005- 2009
• FIGURE 49 PATENTS, SHARE BY TYPE, 2005- 2009 (%)
• FIGURE 50 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005- 2009
• FIGURE 51 TOTAL NUMBER OF PATENTS BY COMPANY, 2005- 2009
• FIGURE 52 NUMBER OF PATENTS BY ASSIGNEE, 2005- 2009